Clinical Trials

Our physicians at Retina Specialists are nationally recognized and actively involved in multi-centered clinical trials on novel therapeutic approaches to vitreoretinal diseases. Our research team is committed to carefully selecting well-designed, safe clinical studies that offer promising and exciting new treatments for our patients. Our clinical trials are a valuable opportunity for patients to access novel treatments for Vitreoretinal diseases.

For more information or to refer a patient for evaluation, please contact our Clinical Trials Coordinator: Debbie Bolling at 972-599-9098 or dbolling@retinaspecialists.net

We participate in numerous active national eye research studies, including:

Diabetic Retinopathy:

KESTREL (Protocol CRTH258B2301): Study of Efficacy and Safety of Brolucizumab v Aflibercept in Patients with Visual Impairment Due to Diabetic Macular Edema
- Clinical Trials.Gov Identifier: NCT03481634
- Principal Investigator: Santosh Patel, MD
- Sponsor: Novartis Pharmaceuticals
- Study Coordinator: Debbie Bolling (dbolling@retinaspecialists.com)
- Status: Not Yet Recruiting or Enrolling

Retinal Vein Occlusion:

TOPAZ (CLS1003-302): Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects with Macular Edema Following RVO

Clinical Trials.Gov Identifier: NCT03203447

o Principal Investigator: Henry Choi, MD

Sponsor: Clearside Biomedical
Study Coordinator: Debbie Bolling (dbolling@retinaspecialists.com)
Status: Active and Recruiting

Age-Related Macular Degeneration:

HAWK STUDY EXTENSION (CRTH258A2301-E1): Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
- Clinical Trials.Gov Identifier: NCT03386474

o Principal Investigator: Santosh C. Patel, MD